At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments.
GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development.